Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 4, 2012, Pages 486-490

  DeBoer, Mark D ^a   Barnes, Barrett H ^a   Stygles, Nicholas A ^a   Sutphen, James L ^a   Borowitz, Stephen M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

adolescent; inflammation; inflammatory bowel disease; infliximab; quality of life

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; ENTERITIS; HUMAN; IMPACT III QUESTIONNAIRE; OUTCOME ASSESSMENT; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCHOOL CHILD; SINGLE DRUG DOSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859111148     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182382ee3     Document Type: Article

References (30)

1. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy inthe treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. (Pubitemid 36576310)
2. Veres G, Baldassano RN, Mamula P. Infliximab therapy inchildren and adolescents with inflammatory bowel disease. Drugs 2007;67:1703-23. (Pubitemid 47263178)
3. Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009;15:388-94.
4. Sinitsky DM, Lemberg DA, Leach ST, et al. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol 2010;25:810-6.
5. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-1166.
6. Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn's disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 2010;50:628-33.
7. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-30. (Pubitemid 46668247)
8. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: avalid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557-63. (Pubitemid 35191077)
9. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22.
10. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
11. Flint A, Raben A, Blundell JE, et al. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000;24:38-48. (Pubitemid 30098877)
12. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002;8:237-43. (Pubitemid 34784975)
13. Ballinger AB, Camacho-Hubner C, Croft NM. Growth failure and intestinal inflammation. Q J Med 2001;94:121-5. (Pubitemid 32241999)
14. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205-10. (Pubitemid 36177114)
15. Brain CE, Savage MO. Growth and puberty inchronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:83-100. (Pubitemid 24133111)
16. Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist innewly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009;48:168-74.
17. Sawczenko A, Ballinger AB, Savage MO, et al. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006;118:124-9. (Pubitemid 46071155)
18. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 2010;139:430-8.
19. Fujimura Y, Honda K, Sato I, et al. Remarkable improvement of growth and developmental retardation in Crohn's disease by parenteral and enteral nutrition therapy. Intern Med 1992;31:39-43.
20. Azooz OG, Farthing MJ, Savage MO, et al. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001;281:R1483-91.
21. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000;46:694-700. (Pubitemid 30305788)
22. DeBoer MD, Li Y, Cohn S. Colitis causes delay inpuberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol 2010;45:277-84.
23. DeBoer MD, Li Y. Puberty isdelayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res 2011;69:34-9.
24. Nappi RE, Rivest S. Effect of immune and metabolic challenges on the luteinizing hormone-releasing hormone neuronal system in cycling female rats: an evaluation at the transcriptional level. Endocrinology 1997;138:1374-84. (Pubitemid 27137082)
25. DeBoer MD, Lafranchi SH. Pediatric thyroid testing issues. Pediatr Endocrinol Rev 2007;5(suppl 1):570-7.
26. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
27. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A 2005;102:13260-5. (Pubitemid 41325011)
28. Beattie RM, Camacho-Hubner C, Wacharasindhu S, et al. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998;49:483-9. (Pubitemid 28475341)
29. Bannerjee K, Camacho-Hubner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004;38:270-5.
30. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.